Allurion Technologies Holdings Inc. has announced findings from two new studies presented at the 2025 Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS). These studies reinforce the efficacy of the Allurion Program, which combines a procedure-less gastric balloon, AI-powered remote support, and real-time digital monitoring, in achieving metabolically healthy weight loss. The data, drawn from nearly 20,000 patients, demonstrate significant fat loss and preservation of muscle mass. Additionally, in one of the longest real-world studies of its kind, patients maintained, on average, 89% of the weight lost during balloon therapy over four years. These results contribute to Allurion's evidence base as the company prepares to complete its FDA submission.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。